' Applicant: Peter J. Wettstein et al.

Attorney's Docket No.: 07039-501US1

Serial No.: To Be Assigned

Filed : Herewith Page : 3 of 7

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Original) A composition comprising a polypeptide and a CpG molecule, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG molecule comprises at least one sulfur atom.
- 2. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.
- 3. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises no more than 15 amino acid residues.

4-5. (Canceled)

- 6. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises a B-X, X-B, or B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.
- 7. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises an B-X-B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.

Applicant: Peter J. Wettstein et al.

Attorney's Docket No.: 07039-501US1

Serial No.: To Be Assigned

Filed : Herewith Page : 4 of 7

8. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least two cysteine residues.

- 9. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least 4 positively charged amino acid residues.
- 10. (Original) The composition of claim 1, wherein at least one of said at least one cysteine residue of said CpG-interacting amino acid sequence is adjacent to a positively charged amino acid residue.
- 11. (Original) The composition of claim 10, wherein said CpG-interacting amino acid sequence comprises the sequence set forth in SEQ ID NO:1 (KCSRNR).
- 12. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:1 (KCSRNR).
- 13. (Original) The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:2 (ACSANA).
- 14. (Original) The composition of claim 13, wherein said at least one positively charged amino acid residue is an arginine.
- 15. (Original) The composition of claim 13, wherein said at least one positively charged amino acid residue is a lysine.
- 16. (Original) The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 50 amino acid residues.

Applicant: Peter J. Wettstein et al.

Attorney's Docket No.: 07039-501US1

Serial No.: To Be Assigned

Filed : Herewith Page : 5 of 7

17-19. (Canceled)

20. (Original) The composition of claim 1, wherein said polypeptide is less than 50 amino acid residues in length.

21-23. (Canceled)

24. (Original) The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate linkage.

25. (Canceled)

- 26. (Original) A method for producing a composition having enhanced immunogenicity, said method comprising:
- (a) obtaining a polypeptide having a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, and wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue; and
- (b) contacting said polypeptide to a CpG molecule comprising a sulfur atom to form said composition.
- 27. (Original) The method of claim 26, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.

28-30. (Canceled)

Applicant: Peter J. Wettstein et al.

Attorney's Docket No.: 07039-501US1

Serial No.: To Be Assigned

Filed : Herewith Page : 6 of 7

31. (Original) A method for activating a cytotoxic T lymphocyte within a mammal, said method comprising administering a composition comprising a polypeptide and a CpG molecule to said mammal, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue, and wherein said CpG molecule comprises a sulfur atom.

32. (Original) The method of claim 31, wherein said CpG-interacting amino acid sequence further comprises at least one positively charged amino acid.

33-37. (Canceled)